Ra Pharmaceuticals Inc RARX Financial and Strategic SWOT Analysis Review [Report Updated: 30082017] Prices from USD $125

09:45 EDT 13 Sep 2017 | BioPortfolio Report Blog

Ra Pharmaceuticals Inc RARX Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Ra Pharmaceuticals Inc Ra Pharmaceuticals is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of diseases caused due to uncontrolled activation of the complement system. The company discovers and develops peptides and small molecules that target key components of the complement cascade. Its lead product candidate, RA101495 is a selfadministered subcutaneous SC injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria PNH. Ra Pharmaceuticals pipeline also includes RA101495, an administered SC, to treat debilitating complementmediated diseases such as refractory generalized myasthenia gravis rMG, and lupus nephritis LN. The company's pipeline products are based on its proprietary peptide chemistry platform. Ra Pharmaceuticals is headquartered on Cambridge, Massachusetts, the US.

Ra Pharmaceuticals Inc Key Recent Developments

Aug 09,2017: Ra Pharmaceuticals Reports Second Quarter 2017 Financial Results
May 11,2017: Ra Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
Mar 06,2017: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Nov 29,2016: Ra Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Apr 06,2016: Ra Pharmaceuticals Appoints Chief Scientific Officer and Expands Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Ra Pharmaceuticals Inc RARX Financial and Strategic SWOT Analysis Review [Report Updated: 30082017] Prices from USD $125


More From BioPortfolio on "Ra Pharmaceuticals Inc RARX Financial and Strategic SWOT Analysis Review [Report Updated: 30082017] Prices from USD $125"

Quick Search

Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...